Patents by Inventor Zhaoguo CHEN

Zhaoguo CHEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF
    Publication number: 20230365558
    Abstract: A series of tetrahydroisoquinoline derivatives and the crystal forms thereof. Specifically disclosed are a compound as represented by formula (VII), a crystal form thereof, and a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 18, 2021
    Publication date: November 16, 2023
    Inventors: Kevin X CHEN, Zuhao GUO, Yanxin YU, Boyu HU, Jingjing WANG, Zhaoguo CHEN, Cheng XIE, Jian XIONG, Yongbo FANG, Yingtao LIU, Jian LI, Shuhui CHEN
  • Crystal form a of (5-amino-8-(2-methyl-6-(trifluoromethyl)pyridin-4-yl)-7-phenyl-[1,2,4]triazolo[1,5-c]pyrimidin-2-yl)methanol (compound 1)
    Patent number: 11649239
    Abstract: Disclosed in the present invention are a crystal form of a [1,2,4]triazolo[1,5-c]pyrimidine compound and a preparation method thereof. Further disclosed is a use of the crystal form in the preparation of a medicament for treating A2A receptor related diseases.
    Type: Grant
    Filed: April 28, 2019
    Date of Patent: May 16, 2023
    Assignee: Medshine Discovery Inc.
    Inventors: Kevin X. Chen, Yanxin Yu, Xinde Chen, Li Zhang, Zhaoguo Chen, Cheng Xie
  • PYRIMIDOPYRROLE SPIRO COMPOUNDS AND DERIVATIVES THEREOF AS DNA-PK INHIBITORS
    Publication number: 20230055321
    Abstract: Provided are a class of DNA-PK inhibitor, and specifically, a compound represented by formula (III) or a pharmaceutically acceptable salt thereof, and use thereof in the preparation of DNA-PK inhibitor-related drugs.
    Type: Application
    Filed: November 20, 2020
    Publication date: February 23, 2023
    Inventors: Kevin X CHEN, Shanghua XIA, Zhaoguo CHEN, Zuhao GUO, Yanxin YU, Kai ZHOU, Boyu HU, Li ZHANG, Fen JIANG, Jingjing WANG, Guoping HU, Jian LI, Shuhui CHEN
  • PYRIMIDOIMIDAZOLE COMPOUNDS USED AS DNA-PK INHIBITORS
    Publication number: 20230026616
    Abstract: A class of DNA-PK inhibitors, in particular a compound represented by formula (IV) or a pharmaceutically acceptable salt thereof, and an application thereof in the preparation of a drug relating to a DNA-PK inhibitor.
    Type: Application
    Filed: November 25, 2020
    Publication date: January 26, 2023
    Inventors: Kevin X CHEN, Shanghua XIA, Zhaoguo CHEN, Zuhao GUO, Yanxin YU, Kai ZHOU, Boyu HU, Li ZHANG, Fen JIANG, Jingjing WANG, Guoping HU, Jian LI, Shuhui CHEN
  • SALT AND CRYSTAL FORM OF MTORC1/2 DUAL KINASE ACTIVITY INHIBITOR AND PREPARATION METHOD THEREFOR
    Publication number: 20220306622
    Abstract: Disclosed are a salt and a crystal form of an mTORC1/2 dual kinase inhibitor and a preparation method therefor. Also disclosed is use of the salt and crystal form in the preparation of a medicament related to the mTORC1/2 dual kinase inhibitor.
    Type: Application
    Filed: May 6, 2020
    Publication date: September 29, 2022
    Inventors: Kevin X CHEN, Zhaoguo CHEN, Li ZHANG, Yanxin YU, Kai ZHOU, Fen JIANG, Shanghua XIA, Xiaofei WANG
  • LSD1 inhibitor and preparation method and application thereof
    Patent number: 11433053
    Abstract: A cyclopropylamine compound as a lysine-specific demethylase 1 (LSD1) inhibitor. Particularly, the present invention relates to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The present invention also provides an application of the same in preparing a drug for treating an LSD1-related disease.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: September 6, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Lingyun Wu, Li Zhang, Lele Zhao, Jianjun Sun, Zhaoguo Chen, Jian Li, Shuhui Chen
  • QUINAZOLINE AND CINNOLINE DERIVATIVES AS DNA-PK INHIBITOR
    Publication number: 20220267310
    Abstract: Disclosed in the present invention are a compound as represented by formula (I), and an isomer or pharmaceutically acceptable salt thereof, and disclosed is an application thereof in preparing drugs for treating DNA-PK inhibitor-related diseases.
    Type: Application
    Filed: June 24, 2020
    Publication date: August 25, 2022
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Kevin X Chen, Zhaoguo Chen, Li Zhang, Boyu Hu, Shuhui Chen
  • Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors
    Patent number: 11377444
    Abstract: Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: July 5, 2022
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Kevin X Chen, Zhaoguo Chen, Li Zhang, Yanxin Yu, Kai Zhou, Boyu Hu, Xiaofei Wang, Guoping Hu, Jian Li, Shuhui Chen
  • SALT FORM AND CRYSTAL FORM OF A2A RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR
    Publication number: 20220185825
    Abstract: Provided are a salt form and a crystal form of adenosine A2A receptor antagonist, and preparation method therefor. Also provided is an application of the salt form or crystal form in the preparation of a medicine for A2A receptor-related diseases, the maleate salt in the salt form has a structure of formula (I).
    Type: Application
    Filed: March 27, 2020
    Publication date: June 16, 2022
    Inventors: Kevin X CHEN, Kai ZHOU, Yanxin YU, Boyu HU, Li ZHANG, Zhaoguo CHEN
  • Sulfonyl-substituted isoquinolines as inhibitors of RHO kinase and hERG potassium channel activity
    Patent number: 11155559
    Abstract: Disclosed are a class of isoquinoline compounds acting as RHO protein kinase inhibitors, and the use thereof in the preparation of a drug for treating diseases associated with RHO protein kinase. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: October 26, 2021
    Assignee: CHINA RESOURCES PHARMACEUTICAL HOLDINGS COMPANY LIMITED
    Inventors: Yuanshan Yao, Li Zhang, Zhaoguo Chen, Lele Zhao, Lingyun Wu, Shuhui Chen
  • PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVES SERVING AS SELECTIVE HER2 INHIBITORS AND APPLICATION THEREOF
    Publication number: 20210323979
    Abstract: The present invention relates to a group of pyrrolo[2,1-f][1,2,4]triazine derivatives serving as selective HER2 inhibitors and an application thereof in the preparation of a drug that serves as an HER2 inhibitor. Specifically, the present invention relates to a compound represented by formula (I), an isomer thereof or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: May 8, 2019
    Publication date: October 21, 2021
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Kevin X CHEN, Fen JIANG, Xinde CHEN, Li ZHANG, Zhaoguo CHEN, Yanxin YU, Kai ZHOU, Boyu HU, Cheng XIE, Shuhui CHEN
  • [1,2,4]triazolo[1,5-c]pyrimidine derivative as Areceptor inhibitor
    Patent number: 11117899
    Abstract: Provided are a compound represented by formula (I), an isomer or a pharmaceutically acceptable salt thereof, and an application of the same in preparing a drug for treating a disease related to A2A receptor. The R1, R2, R3, ring A, ring B, n, and m are as defined in the specification.
    Type: Grant
    Filed: April 8, 2018
    Date of Patent: September 14, 2021
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Kevin X Chen, Yanxin Yu, Xinde Chen, Li Zhang, Zhaoguo Chen, Cheng Xie, Xiaofei Wang, Linghui Wu, Guoping Hu, Jian Li, Shuhui Chen
  • [1,2,4]triazolo[1,5-c]pyrimidine derivative as Areceptor inhibitor
    Patent number: 11066411
    Abstract: Provided are a compound represented by formula (I), an isomer or a pharmaceutically acceptable salt thereof, and an application of the same in preparing a drug for treating a disease related to A2A receptor. The R1, R2, R3, ring A, ring B, n, and m are as defined in the specification.
    Type: Grant
    Filed: April 8, 2018
    Date of Patent: July 20, 2021
    Assignee: MEDSHINE DISCOVERY INC.
    Inventors: Kevin X Chen, Yanxin Yu, Xinde Chen, Li Zhang, Zhaoguo Chen, Cheng Xie, Xiaofei Wang, Linghui Wu, Guoping Hu, Jian Li, Shuhui Chen
  • Dimethylphosphine oxide compound
    Patent number: 11046720
    Abstract: Disclosed is an application of a series of dimethylphosphine oxide compounds in the preparation of an LRRK2 kinase activity inhibitor-related drug, specifically an application of the compound shown in formula (I) or a pharmaceutically acceptable salt thereof in the preparation of an LRRK2 kinase activity inhibitor-related drug.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: June 29, 2021
    Assignee: GUIZHOU INOCHINI TECHNOLOGY CO., LTD
    Inventors: Lingyun Wu, XiaWei Wei, Peng Zhang, Zhaoguo Chen, Cailin Wang, Lele Zhao, Jian Li, Shuhui Chen
  • DIMETHYLPHOSPHINE OXIDE COMPOUND
    Publication number: 20210147453
    Abstract: Disclosed is an application of a series of dimethylphosphine oxide compounds in the preparation of an LRRK2 kinase activity inhibitor-related drug, specifically an application of the compound shown in formula (I) or a pharmaceutically acceptable salt thereof in the preparation of an LRRK2 kinase activity inhibitor-related drug.
    Type: Application
    Filed: April 19, 2019
    Publication date: May 20, 2021
    Applicant: GUIZHOU INOCHINI TECHNOLOGY CO., LTD
    Inventors: Lingyun WU, XiaWei WEI, Peng ZHANG, Zhaoguo CHEN, Cailin WANG, Lele ZHAO, Jian LI, Shuhui CHEN
  • CRYSTAL FORM AND SALT TYPE OF TRIAZOLOPYRIMIDINE COMPOUND AND PREPARATION METHOD THEREOF
    Publication number: 20210094957
    Abstract: Disclosed in the present invention are a crystal form of a [1,2,4]triazolo[1,5-c]pyrimidine compound and a preparation method thereof. Further disclosed is a use of the crystal form in the preparation of a medicament for treating A2A receptor related diseases.
    Type: Application
    Filed: April 28, 2019
    Publication date: April 1, 2021
    Applicant: Medshine Discovery Inc.
    Inventors: Kevin X. Chen, Yanxin Yu, Xinde Chen, Li Zhang, Zhaoguo Chen, Cheng Xie
  • QUINAZOLINE DERIVATIVE AND USE THEREOF
    Publication number: 20210078958
    Abstract: The present invention relates to a series of quinazoline compounds, especially compounds as represented by formula (I), isomers thereof or pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, and use thereof as Pan-HER tyrosine kinase inhibitors.
    Type: Application
    Filed: December 19, 2018
    Publication date: March 18, 2021
    Applicant: Medshine Discovery Inc.
    Inventors: Kevin X. CHEN, XiaWei WEI, Li ZHANG, Yanxin YU, Kai ZHOU, Boyu HU, Zhaoguo CHEN, Huiyu ZHANG, Shuhui CHEN
  • LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF
    Publication number: 20200345700
    Abstract: A cyclopropylamine compound as a lysine-specific demethylase 1 (LSD1) inhibitor. Particularly, the present invention relates to a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. The present invention also provides an application of the same in preparing a drug for treating an LSD1-related disease.
    Type: Application
    Filed: January 24, 2018
    Publication date: November 5, 2020
    Applicant: MEDSHINE DISCOVERY INC.
    Inventors: Lingyun WU, Li ZHANG, Lele ZHAO, Jianjun SUN, Zhaoguo CHEN, Jian Ll, Shuhui CHEN
  • PYRIDOPYRIMIDINE COMPOUNDS ACTING AS MTORC 1/2 DOUBLE-KINASE INHIBITORS
    Publication number: 20200339568
    Abstract: Disclosed are a series of pyridopyrimidine compounds and a use of same in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors, and specifically disclosed is a use of the compounds as shown in formula (IV), tautomers thereof or pharmaceutically acceptable salts thereof in the preparation of drugs associated with mTORC 1/2 dual complex inhibitors.
    Type: Application
    Filed: November 2, 2018
    Publication date: October 29, 2020
    Inventors: Kevin X CHEN, Zhaoguo CHEN, Li ZHANG, Yanxin YU, Kai ZHOU, Boyu HU, Xiaofei WANG, Guoping HU, Jian LI, Shuhui CHEN
  • ISOQUINOLINYLSULFONYL DERIVATIVE AND USE THEREOF
    Publication number: 20200207772
    Abstract: Disclosed are a class of isoquinoline compounds acting as RHO protein kinase inhibitors, and the use thereof in the preparation of a drug for treating diseases associated with RHO protein kinase. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: July 18, 2018
    Publication date: July 2, 2020
    Inventors: Yuanshan YAO, Li ZHANG, Zhaoguo CHEN, Lele ZHAO, Lingyun WU, Shuhui CHEN